Arbutus Biopharma Corporation (ABUS)Healthcare | Biotechnology | Warminster, United States | NasdaqGS
4.67 USD
-0.14
(-2.813%) ⇩
(July 13, 2026, 4 p.m.
EDT)
After hours: 4.89 +0.22 (4.727%) ⇧ (July 13, 2026, 7:59 p.m. EDT) |
Hot Take ↕ | July 11, 2026, 6:54 a.m. EDT
The immediate outlook is neutral-to-slightly-bearish due to a lack of clear directional momentum. While the stock recently rallied from its lows, the recent price action shows a pullback, and the statistical forecast model offers virtually no predictive power, rendering it useless for timing. The heavy put volume suggests traders are hedging against further declines or waiting for a failed attempt to break above $5.00. Long-term, the investment case remains unproven. Despite impressive headline numbers like 100% revenue growth and high margins, these figures reflect a tiny base typical of early-stage biotechs, not sustainable scale. The company is burning significant cash, with free cash flow deeply negative and no path to profitability indicated by the negative forward earnings estimate. The balance sheet, while currently liquid, cannot sustain indefinite burn without dilution or a successful clinical trial. The multi-year price trajectory confirms the market's skepticism, showing a net decline over the last nine years despite the recent uptick. Without a catalyst to turn the cash burn into commercial revenue, the risk of permanent capital loss outweighs the potential for recovery. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.039954 |
| AutoETS | 0.041395 |
| AutoARIMA | 0.042059 |
| MSTL | 0.042450 |
| MSTL_63 | 0.043488 |
| MSTL_36 | 0.053571 |
| MSTL_36_63 | 0.060131 |
Forecast horizon: 60 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 29% |
| H-stat | 5.40 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.001 |
| Excess Kurtosis | 0.87 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 1.502 |
| Revenue per Share | 0.995 |
| Market Cap | 921,513,408 |
| Trailing P/E | 5.62 |
| Forward P/E | -28.22 |
| Beta | 0.62 |
| Profit Margins | 83.95% |
| Website | https://www.arbutusbio.com |
As of July 11, 2026, 6:54 a.m. EDT: Speculators are heavily positioned for downside protection, with massive open interest in out-of-the-money puts expiring in September and January, creating a 'pin risk' zone around $4.00-$4.50. Conversely, call activity is concentrated in the $5.00-$6.00 range, suggesting a speculative bet on a bounce to the $5 level rather than a sustained rally. The imbalance indicates a market expecting volatility or a drop below current prices rather than a breakout.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.48148143 |
| Address1 | 701 Veterans Circle |
| All Time High | 31.48 |
| All Time Low | 0.82 |
| Ask | 6.02 |
| Ask Size | 2 |
| Audit Risk | 4 |
| Average Daily Volume10 Day | 3,512,610 |
| Average Daily Volume3 Month | 2,152,398 |
| Average Volume | 2,152,398 |
| Average Volume10Days | 3,512,610 |
| Beta | 0.618 |
| Bid | 3.44 |
| Bid Size | 2 |
| Board Risk | 7 |
| Book Value | 1.321 |
| City | Warminster |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 8 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 4.665 |
| Current Ratio | 54.263 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 4.85 |
| Day Low | 4.655 |
| Debt To Equity | 1.502 |
| Display Name | Arbutus Biopharma |
| Earnings Call Timestamp End | 1,730,900,700 |
| Earnings Call Timestamp Start | 1,730,900,700 |
| Earnings Timestamp | 1,778,675,400 |
| Earnings Timestamp End | 1,785,933,000 |
| Earnings Timestamp Start | 1,785,933,000 |
| Ebitda | 155,136,992 |
| Ebitda Margins | 0.81035006 |
| Enterprise To Ebitda | 5.351 |
| Enterprise To Revenue | 4.336 |
| Enterprise Value | 830,196,416 |
| Eps Current Year | -0.219 |
| Eps Forward | -0.16528323 |
| Eps Trailing Twelve Months | 0.83 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 4.4694 |
| Fifty Day Average Change | 0.19560003 |
| Fifty Day Average Change Percent | 0.04376427 |
| Fifty Two Week Change Percent | 48.148144 |
| Fifty Two Week High | 5.38 |
| Fifty Two Week High Change | -0.71500015 |
| Fifty Two Week High Change Percent | -0.13289966 |
| Fifty Two Week Low | 3.08 |
| Fifty Two Week Low Change | 1.585 |
| Fifty Two Week Low Change Percent | 0.5146104 |
| Fifty Two Week Range | 3.08 - 5.38 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,185,456,600,000 |
| Float Shares | 121,369,144 |
| Forward Eps | -0.16528323 |
| Forward P E | -28.224277 |
| Free Cashflow | -90,406,624 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 19 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 0.89343 |
| Gross Profits | 171,043,008 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.20459 |
| Held Percent Institutions | 0.71918 |
| Implied Shares Outstanding | 197,537,710 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,288,828,800 |
| Last Split Factor | 1:5 |
| Long Business Summary | Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients' HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania. |
| Long Name | Arbutus Biopharma Corporation |
| Market | us_market |
| Market Cap | 921,513,408 |
| Market State | POSTPOST |
| Max Age | 86,400 |
| Message Board Id | finmb_34160168 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | 160,720,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 948,181,008 |
| Number Of Analyst Opinions | 2 |
| Open | 4.79 |
| Operating Cashflow | -34,356,000 |
| Operating Margins | 0.94412005 |
| Overall Risk | 6 |
| Payout Ratio | 0.0 |
| Phone | 267 469 0914 |
| Post Market Change | 0.22049999 |
| Post Market Change Percent | 4.726688 |
| Post Market Price | 4.8855 |
| Post Market Time | 1,783,987,187 |
| Previous Close | 4.8 |
| Price Eps Current Year | -21.30137 |
| Price Hint | 4 |
| Price To Book | 3.5314157 |
| Price To Sales Trailing12 Months | 4.813463 |
| Profit Margins | 0.83950996 |
| Quick Ratio | 54.002 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.135 |
| Regular Market Change Percent | -2.8125 |
| Regular Market Day High | 4.85 |
| Regular Market Day Low | 4.655 |
| Regular Market Day Range | 4.655 - 4.85 |
| Regular Market Open | 4.79 |
| Regular Market Previous Close | 4.8 |
| Regular Market Price | 4.665 |
| Regular Market Time | 1,783,972,801 |
| Regular Market Volume | 1,349,835 |
| Return On Assets | 0.49183 |
| Return On Equity | 0.94727 |
| Revenue Growth | 100.545 |
| Revenue Per Share | 0.995 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 5 |
| Shares Outstanding | 197,537,710 |
| Shares Percent Shares Out | 0.0866 |
| Shares Short | 17,111,453 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 16,982,764 |
| Short Name | Arbutus Biopharma Corporation |
| Short Percent Of Float | 0.1289 |
| Short Ratio | 7.29 |
| Source Interval | 15 |
| State | PA |
| Symbol | ABUS |
| Target High Price | 5.3449106 |
| Target Low Price | 4.8354 |
| Target Mean Price | 5.090155 |
| Target Median Price | 5.090155 |
| Total Cash | 95,226,000 |
| Total Cash Per Share | 0.482 |
| Total Debt | 3,909,000 |
| Total Revenue | 191,444,992 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 0.83 |
| Trailing P E | 5.620482 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 4.44175 |
| Two Hundred Day Average Change | 0.22324991 |
| Two Hundred Day Average Change Percent | 0.050261702 |
| Type Disp | Equity |
| Volume | 1,349,835 |
| Website | https://www.arbutusbio.com |
| Zip | 18,974 |